NeuLife Laboratories Introduces Eczana an AllNatural Weapon Designed for the Fight Against Eczema Psoriasis Dermatitis and Other Skin Conditions



May 9, 2005 -- Eczana is the latest product from the up and coming NeuLife Laboratories. NeuLife, makers of Neugenisis and Neuderma, the Antiaging "Longevity System", have developed a special formula, exclusive of harsh medicinal chemicals and steroids.

Eczana includes 2 very effective and proven ingredients to combat the cruel conditions associated with eczema, psoriasis, and dermatitis. Eczana includes Canadian Willowherb and Oregon Grape extracts to provide a unique soothing and healing topical cream.

The enornmous immediate response of Eczana has propelled NeuLife Laboratories even further to the forefront of strong companies producing quality, highly effective products sold directly to the consumer.

NeuLife Labs released the following statement "After the success of our Antiaging/HGH stimulating formula and Antiaging/antiwrinkle cream, we wanted to provide consumers who are afflicted with this uncomfortable and endless condition with a product derived from entirely from nature. Our ingredients have been used for centuries to combat these conditions. We just formulated an effective combination and introduced it to the public. Eczana is truely unique and is virtually side-effect free. We are extremely proud of our growing product line."

Eczana is sure to emerge as one of the leading eczema creams available for use without a prescription.








***Note This page is an Archieve of Publicly released information either through our company or another Press Release organization. We do not "fact check", "Support", nor "Dispute" any of the information provided to us. We are a distribution point and Historical press release research and search service. This information only represents the fact that at one point in time the release was distributed to 1000's of publications both online and off. PRNewsNow will not take sides in any personal or commercial disputes you have with the writer of this press release. We will defend its right to exist blindly and without regards to its political, commercial or personal implications.***